Century Therapeutics

Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. It engages in harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. The company was founded by Marcela Maus and Hiromitsu Nakauchi in 2018 and is headquartered in Philadelphia, PA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. It focuses on harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. The company was founded by Marcela Maus and Hiromitsu Nakauchi in 2018 and is headquartered in Philadelphia, PA.

PHILADELPHIA, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Lalo Flores, Ph.D., Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29, 2022, at 2:00 PM ET.

Century Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference

- Preclinical data support next generation platform for iPSC-derived NK cells with multiple gene edits to improve persistence and anti-tumor efficacy -

Century Therapeutics Announces Presentation of Preclinical Data at the SITC 37th Annual Meeting and Provides Pipeline Updates

- Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell malignancies expected to begin imminently -

Century Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

PHILADELPHIA, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics  (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that it will host a virtual Research and Development (R&D) Day on Friday, November 11, 2022, from 8:00 AM to 9:30 AM ET.

Century Therapeutics to Host Virtual Research and Development Day on November 11, 2022

PHILADELPHIA, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics  (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that preclinical data from the Company's iPSC-based cell therapy platform will be presented in two posters at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, on November 8-12, 2022 in Boston, Massachusetts.

Century Therapeutics to Present at the SITC 37th Annual Meeting

PHILADELPHIA, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the appointment of Daphne Quimi and Timothy Walbert to the Company's Board of Directors. Ms. Quimi is currently Chief Financial Officer of Amicus Therapeutics and brings experience in public accounting and financial reporting to Century. Mr. Walbert is currently Chairman, President, and Chief Executive Officer of Horizon Therapeutics, and brings expertise in product portfolio building and commercialization. In conjunction with these new appointments, Century also announced that Eli Casdin, Chief Investment Officer of Casdin Capital, has resigned from the Board of Directors, effective as of October 1, 2022.

Century Therapeutics Announces Appointment of Daphne Quimi and Timothy Walbert to its Board of Directors

PHILADELPHIA, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Lalo Flores, Ph.D., Chief Executive Officer, will participate in a panel titled “Next Generation Gene Editing” at Chardan's 6th Annual Genetic Medicines Conference on Monday, October 3, 2022, at 10:30 AM ET.

Century Therapeutics to Present at Chardan's 6th Annual Genetic Medicines Conference

PHILADELPHIA, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Adrienne Farid, Ph.D., Chief Operations Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference on Tuesday, September 13, 2022 at 9:00 AM ET.

Century Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

– Investigational New Drug Application for CNTY-101, a CAR-iNK product candidate targeting CD19 for B-cell malignancies, cleared by FDA –

Century Therapeutics Receives Study May Proceed Notification from FDA for CNTY-101, the First Allogeneic Cell Therapy Product Candidate Engineered to Overcome Three Major Pathways of Host vs Graft Rejection

- Following the recent submission of the IND application for CNTY-101 and pending FDA clearance, the Phase 1 ELiPSE-1 trial in relapsed/refractory lymphoma is on track to commence in the second half of 2022 -

Century Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates

PHILADELPHIA, June 24, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that it is set to join the Russell Microcap Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective after the U.S. market opens on June 27, 2022.

Century Therapeutics Announces Its Addition to the Russell Microcap® Index

PHILADELPHIA, June 21, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Lalo Flores, Ph.D., Chief Executive Officer, will participate in a fireside chat at the LifeSci Partners 2nd Annual Genetic Medicines Symposium on June 28, 2022, at 9:30 AM ET.

Century Therapeutics to Present at the LifeSci Partners 2nd Annual Genetic Medicines Symposium

PHILADELPHIA, June 06, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that it will host a virtual Research and Development (R&D) Day on Monday, June 13, 2022, from 4:30 PM to 6:00 PM ET.

Century Therapeutics to Host Virtual Research and Development Day on June 13, 2022

- Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory lymphoma expected to commence in the second half of 2022 following IND submission in mid 2022-

Century Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates

PHILADELPHIA, May 02, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that preclinical data on MAD7, a novel CRISPR nuclease used to enable the genetic engineering of iPSC-derived NK and T cell product candidates, will be presented in a poster at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting, on May 16-19, 2022 in Washington, D.C.

Century Therapeutics to Present at the ASGCT 25th Annual Meeting

PHILADELPHIA, April 18, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that members of the management team will present at the virtual Chardan Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 25, 2022, at 9:30 AM ET.

Century Therapeutics to Present at the Chardan Genetic Medicines and Cell Therapy Manufacturing Summit

PHILADELPHIA, April 06, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Lalo Flores, Ph.D., Chief Executive Officer, will present at the 21st Annual Needham Virtual Healthcare Conference on April 13, 2022, at 10:15 AM ET and participate in a panel titled “Company Perspectives: Companies Discussing Key Features and Differentiators in the NK Cellular Therapeutics Space” on April 14, 2022, at 11:00 AM ET.

Century Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

PHILADELPHIA, March 23, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Lalo Flores, Ph.D., Chief Executive Officer, will present at the H.C. Wainwright Gene Therapy and Gene Editing Conference, being held virtually on March 30, 2022.

Century Therapeutics to Present at the H.C. Wainwright Gene Therapy and Gene Editing Conference

IND submission for lead program CNTY-101 on track for mid 2022; Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory lymphoma expected to commence after IND submission

Century Therapeutics Reports Fourth Quarter and Year-end 2021 Financial Results and Provides Business Updates

PHILADELPHIA, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that members of the senior management team will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 1:40 PM ET.

Century Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Fate Therapeutics

Natural-killer cell therapy is one of the most recent paradigms in cancer treatment, and two prominent companies working on this new technology are Fate Therapeutics Inc  FATE and Century Therapeutics Inc  IPSC, an analyst at BofA Securities said in a note on Tuesday. The Biopharma Analyst: Tazeen Ahmad has a Buy rating and $112 price target on Fate shares.

2 Natural-Killer Cell Therapy Oncology Companies Investors Should Watch

The stock price of Century Therapeutics Inc (NASDAQ: IPSC) increased by 14.52% in the most recent trading session. This is why it happened.

Century Therapeutics Stock (IPSC): Why The Price Increased

Bristol-Myers

Century Therapeutics Inc (NASDAQ: IPSC) and Bristol Myers Squibb Co (NYSE: BMY) have announced a research collaboration and license agreement for up to four induced pluripotent stem cell (iPSC) programs for hematologic malignancies and solid tumors.  The first two programs include a program in acute myeloid leukemia and a program in multiple myeloma, which could incorporate either the iNK or a gamma delta iT platform.

Bristol Myers, Century Therapeutics Ink Pact For iPSC-Derived Allogeneic Cell Therapies

PHILADELPHIA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Lalo Flores, Ph.D., Chief Executive Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 1:30 PM ET.

Century Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

PHILADELPHIA, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI), effective as of market open on Monday, December 20, 2021.

News for Century Therapeutics Stock (IPSC)